Characteristics of the patients included in the study compared with those who refused to participate
Characteristics . | Patients included in the study . | Patients who refused to participate . | P . |
|---|---|---|---|
| No. of patients | 39 | 18 | NA |
| Median age at transplantation, y (range) | 25 (5-56) | 39 (8-63) | .006 |
| Median age at the examination, y (range) | 34 (20-59) | 46 (20-65) | .009 |
| Median follow-up after HSCT, y (range) | 9 (2-20) | 8 (2-18) | NS |
| Diagnosis, no. (%) | NS | ||
| Severe aplastic anemia | 3 (8) | 1 (6) | |
| Hematologic malignancies | 36 (92) | 17 (94) | |
| Acute myeloblastic leukemia | 17 | 4 | |
| Chronic myeloid leukemia/other MPS | 11/0 | 7/1 | |
| Acute lymphoblastic leukemia | 4 | 2 | |
| Multiple myeloma | 2 | 0 | |
| Myelodysplastic syndrome | 1 | 1 | |
| Hodgkin disease/non-Hodgkin lymphoma | 1/0 | 0/2 | |
| Type of conditioning, no. (%) | NS | ||
| Cyclophosphamide and TBI 10 Gy or more | 32 (82) | 14 (78) | |
| Fludarabine and TBI 2 Gy | 3 (8) | 1 (5.5) | |
| Cyclophosphamide alone | 3 (8) | 1 (5.5) | |
| Cyclophosphamide and busulfan | 1 (2) | 2 (11) | |
| Source of stem cells, no. (%) | NS | ||
| Peripheral blood | 11 (28) | 8 (44) | |
| Bone marrow | 28 (72) | 10 (56) | |
| Donor type, no. (%) | NS | ||
| Matched sibling | 32 (82) | 16 (89) | |
| Mismatched related | 0 | 1 (5.5) | |
| Matched unrelated | 7 (18) | 1 (5.5) | |
| Acute GvHD, no. (%) | NS | ||
| None or grade I | 8 (21) | 9 (50) | |
| Grade II-IV | 31 (79) | 9 (50) | |
| Chronic GvHD at any time of follow-up, no. (%) | NS | ||
| None | 21 (54) | 9 (50) | |
| Yes | 18 (46) | 9 (50) | |
| Paternity before HSCT, no. (%) | .003 | ||
| None | 29 (74) | 6 (33) | |
| Yes | 10 (26) | 12 (67) | |
| Patients with 2 or more children, no. (%) | 8 (21) | 10 (56) | .008 |
Characteristics . | Patients included in the study . | Patients who refused to participate . | P . |
|---|---|---|---|
| No. of patients | 39 | 18 | NA |
| Median age at transplantation, y (range) | 25 (5-56) | 39 (8-63) | .006 |
| Median age at the examination, y (range) | 34 (20-59) | 46 (20-65) | .009 |
| Median follow-up after HSCT, y (range) | 9 (2-20) | 8 (2-18) | NS |
| Diagnosis, no. (%) | NS | ||
| Severe aplastic anemia | 3 (8) | 1 (6) | |
| Hematologic malignancies | 36 (92) | 17 (94) | |
| Acute myeloblastic leukemia | 17 | 4 | |
| Chronic myeloid leukemia/other MPS | 11/0 | 7/1 | |
| Acute lymphoblastic leukemia | 4 | 2 | |
| Multiple myeloma | 2 | 0 | |
| Myelodysplastic syndrome | 1 | 1 | |
| Hodgkin disease/non-Hodgkin lymphoma | 1/0 | 0/2 | |
| Type of conditioning, no. (%) | NS | ||
| Cyclophosphamide and TBI 10 Gy or more | 32 (82) | 14 (78) | |
| Fludarabine and TBI 2 Gy | 3 (8) | 1 (5.5) | |
| Cyclophosphamide alone | 3 (8) | 1 (5.5) | |
| Cyclophosphamide and busulfan | 1 (2) | 2 (11) | |
| Source of stem cells, no. (%) | NS | ||
| Peripheral blood | 11 (28) | 8 (44) | |
| Bone marrow | 28 (72) | 10 (56) | |
| Donor type, no. (%) | NS | ||
| Matched sibling | 32 (82) | 16 (89) | |
| Mismatched related | 0 | 1 (5.5) | |
| Matched unrelated | 7 (18) | 1 (5.5) | |
| Acute GvHD, no. (%) | NS | ||
| None or grade I | 8 (21) | 9 (50) | |
| Grade II-IV | 31 (79) | 9 (50) | |
| Chronic GvHD at any time of follow-up, no. (%) | NS | ||
| None | 21 (54) | 9 (50) | |
| Yes | 18 (46) | 9 (50) | |
| Paternity before HSCT, no. (%) | .003 | ||
| None | 29 (74) | 6 (33) | |
| Yes | 10 (26) | 12 (67) | |
| Patients with 2 or more children, no. (%) | 8 (21) | 10 (56) | .008 |
NS indicates not significant; MPS, myeloproliferative syndrome; and NA, not applicable.